Stay updated on Telisotuzumab vs Docetaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Telisotuzumab vs Docetaxel in NSCLC Clinical Trial page.

Latest updates to the Telisotuzumab vs Docetaxel in NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe Study Details page update reorganizes the site network by adding new locations (Santa Monica, Porto Alegre, Lyon, Gothenburg) and removing or revising others, reflecting changes in where the trial is conducted. It also adds new help sections (Check who can join, Find Contact Information, How to Read a Study Record, Common Questions, How to Join a Study) and updates the revision to v3.6.0 on 2026-06-11.SummaryDifference0.3%

- Check17 days agoChange DetectedThe Gothenburg site in Sweden has its recruitment status updated from Active, not recruiting to Completed as of 2026-06-02, with the postal code corrected to 41346. The page revision to v3.5.5 records this change and updates the location data accordingly.SummaryDifference0.1%

- Check24 days agoChange DetectedA new trial site Grand Hopital de Charleroi - Les Viviers (ID# 234178) was added with a Completed status on 2026-06-01, following earlier entries showing the site as Recruiting/Active, not recruiting on 2026-05-19 and 2026-05-22.SummaryDifference0.1%

- Check31 days agoChange DetectedTwo study sites were updated: Ordensklinikum Linz Elisabethinen and Hospital Pablo Tobón Uribe progressed from Recruiting to Completed, indicating they are no longer enrolling participants as of mid-May 2026; the changes reflect recruitment status updates over the 14–22 May 2026 period.SummaryDifference0.1%

- Check39 days agoChange DetectedNew recruitment sites were added (e.g., UZ Gent in Belgium and Hospital Sirio Libanes in Sao Paulo) and the total number of locations is updated to 317, reflecting expanded global participation. Expanded Access status is shown as Temporarily not available and older contact entries were removed.SummaryDifference0.4%

- Check60 days agoChange DetectedThe site footer revision number has been updated from v3.5.2 to v3.5.3, reflecting a minor platform/document version update rather than any change to the clinical study information.SummaryDifference0.0%

Stay in the know with updates to Telisotuzumab vs Docetaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Telisotuzumab vs Docetaxel in NSCLC Clinical Trial page.